Document is current

Article History

Accepted: 10 August 2022

First Online: 28 September 2022

Declarations

:

: This work was supported by Celltrion, Inc. (Incheon, Republic of Korea). The study sponsor played a role in the study design, data collection and analysis, decision to publish, and preparation of the manuscript.

: Fedor Moiseenko has received support for travel to meetings from AstraZeneca, Biocad, MSD, Novartis, Pfizer, and Roche; payment for lectures, including service on speakers’ bureaus, from AstraZeneca, Biocad, Eli Lilly, MSD, Novartis, Pfizer, and Roche; and has provided expert testimony for AstraZeneca, BMS, Eli Lilly, and Roche. SungHyun Kim, KeumYoung Ahn, and TaeHong Park are employees of and hold stocks in Celltrion, Inc. Sijin Park and Hana Ju are employees of Celltrion, Inc. Yuichiro Ohe has received grants from AstraZeneca, BMS, Chugai, Daiichi-Sankyo, Dainippon-Sumitomo, Janssen, Kissei, Kyorin, Lilly, LOXO, Novartis, ONO, Pfizer, Taiho, and Takeda; consulting fees or honoraria from AstraZeneca, Bayer, BMS, Boehringer Ingelheim, Chugai, Eli Lilly, Kyowa Hakko Kirin, MSD, Nippon Kayaku, ONO, Pfizer, and Taiho; fees for participation in review activities such as data monitoring boards from Amgen, AnHeart Therapeutics Inc., AstraZeneca, BMS, Boehringer Ingelheim, Celltrion, Chugai, Kyorin, Nippon Kayaku, and ONO; payment for the writing or reviewing of manuscripts from Eisai; and payment for lectures including service on speakers’ bureaus from AstraZeneca, Bayer, BMS, Boehringer Ingelheim, Chugai, Eli Lilly, Kyowa Hakko Kirin, MSD, Nippon Kayaku, ONO, Pfizer, and Taiho. Claire Verschraegen, Zoran Andric, Tamta Makharadze, Sergii Shevnya, Alona Oleksiienko, and Eduardo Yañez Ruiz have no conflicts of interest to declare.

: All data generated or analyzed during this study are included in this published article and its supplementary information files.

: Not applicable.

: This study was conducted in accordance with the ethical principles originating in the Declaration of Helsinki, International Conference on Harmonisation Good Clinical Practice guidelines, and all applicable regulations. Prior to study initiation, the protocol was approved by the relevant Institutional Review Board or independent Ethics Committee at each center.

: Informed written consent to participate in this study was obtained from all participants.

: All participants provided consent for their data to be published.